Sheffield-based Silvia Bio raises £3m led by Northern Gritstone and Parkwalk
This article covers Silvia Bio, a healthtech startup spun out of the University of Sheffield, and its £3m seed funding round to commercialise a cell profiling platform. The funding aims to help biopharma companies boost yields, reduce variability and shorten manufacturing delays for complex biologics.
Silvia Bio, a healthtech startup spun out of the University of Sheffield, has raised £3 million in a seed funding round to commercialise a cell‑profiling platform designed to help biopharma companies boost yields, reduce variability and shorten manufacturing delays for complex biologics.
Why it matters
Manufacturing bottlenecks are an increasingly common constraint for modern biologics. As antibody formats, gene therapies and other complex molecules become more sophisticated, mammalian cell factories can struggle to produce them consistently, producing low yields, variable quality and costly delays. For biopharmaceutical companies, each day a medicine is delayed can represent around £500,000 in lost sales, and more than half of new biological medicines are now considered difficult to manufacture. Improving predictability in production therefore matters for both commercial viability and patient access.
Inside the product
Silvia Bio’s platform combines proprietary cell profiling with formulation work to identify biological bottlenecks and create media additives that can be introduced into bioreactors. The company says its profiling creates a detailed fingerprint of cell behaviour during manufacturing, which it uses to design licensable, bioreactor‑compatible additives aimed at improving yield and critical quality attributes across antibodies, vaccines and gene therapies.
The startup has already validated the platform with industrial partners. The new capital will fund a move into dedicated laboratory space at Sheffield’s Innovation Centre, the automation of processes currently carried out manually, an increase in commercial capacity and the development of new licensable products for international customers.
Who are the investors?
The £3 million seed round was led by Northern Gritstone, with participation from the Parkwalk Northern Universities Venture Fund, the UK Innovation & Science Seed Fund (managed by Future Planet Capital), Wren Capital and angel investors.
Northern Gritstone led the round and will provide both capital and venture builder support through its NG Studios programme. Parkwalk’s fund targets spinouts from northern universities. The UK Innovation & Science Seed Fund is managed by Future Planet Capital and focuses on early‑stage commercialisation; Wren Capital and unnamed angels add further early‑stage backing.
In the announcement, Duncan Johnson, CEO at Northern Gritstone, said:
Silvia Bio is tackling a critical bottleneck in the development of next-generation medicines. Its technology combines deep scientific insight with a clear commercial proposition: helping manufacturers improve yields, reduce delays and make complex biologics more predictable to produce. Building on world-class research from the University of Sheffield and the support of our venture builder programme, NG Studios, Ed, Melinda and the team have made impressive progress, and we are delighted to support their next phase of growth.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
Silvia Bio was founded by Ed Curry, Melinda Pohle, Adam Brown and David James, building on more than 20 years of biomanufacturing research at the University of Sheffield. The company plans to triple headcount and scale automation as it moves into commercial labs.
In the announcement, Ed Curry, Co-founder & CEO at Silvia Bio, said:
The medicines being developed today have the potential to transform patients’ lives, but many are becoming harder and more expensive to manufacture. Our platform gives biopharmaceutical companies a much clearer view of why their cells are underperforming and, crucially, provides practical solutions that can be introduced directly into the manufacturing process. This investment will allow us to automate and scale our technology, grow our team and help more companies bring complex medicines to patients faster.
The bigger picture
The funding reflects ongoing momentum for university spinouts translating academic biomanufacturing research into commercial tools that de‑risk production of next‑generation therapies. The deal also highlights sustained interest from healthtech investors in platform approaches that aim to address upstream manufacturing risk rather than only downstream process improvements.
As the UK and European biotech sectors push further into advanced modalities, solutions that make production more predictable will be important for keeping the region competitive and for getting complex medicines to patients more quickly.
They've invested in Silvia Bio
Get to know these healthtech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 | ||||
 Parkwalk Northern Universities Venture Fund( ) | ||||
 UK Innovation & Science Seed Fund( ) , US  | ||||
 Wren Capital( ) Wren is an angel investor founded in 2011, focusing on sectors such as science, ... London  | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK